Coronary Artery DiseaseNCT07814157
PCI Registry Basel
An observational study of Coronary Artery Disease and Coronary Stenosis, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
This registry aims to learn more about the best ways to treat coronary artery disease. Information from routine medical care will be collected to compare different treatment approaches, including drug-eluting stents, drug-coated balloons (DCB), and bioresorbable scaffolds (BRS), which gradually dissolve over time. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease, Coronary Stenosis, Coronary Occlusion
- How many people
- 10,000 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Oct 2025to Oct 2035
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consits of patients undergoing percutaneous coronary interventions (PCI) at the University Hospital Basel
Who may be able to join
- Patients treated at the University Hospital Basel
- Undergoing complex PCI (e.g. left main, bifurcation, multivessel PCI, rotational atherectomy or other calcium modification, complex anatomy). The definition complex will be a clinical/ procedural/ anatomical definition made by the operator.
- Undergoing CTO or CHIP (Complex High-risk Indicated Patient) procedures
- Treated with a DCB strategy
- Treated with a BRS
Who cannot join
- Patients under 18 years of age
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
University Hospital Basel
Basel, Canton of Basel-City, 4031
Gregor Leibundgut, Prof. Dr. med., (0)61 556 58 18 ext. 0041, gregor.leibundgut@usb.ch
Jasper Boeddinghaus, PD Dr. med., (0)61 328 78 97 ext. 0041, jasper.boeddinghaus@usb.ch
About this study
This registry aims to learn more about the best ways to treat coronary artery disease. Information from routine medical care will be collected to compare different treatment approaches, including drug-eluting stents, drug-coated balloons (DCB), and bioresorbable scaffolds (BRS), which gradually dissolve over time. The registry will include people with coronary artery disease who receive an intervention (percutaneous coronary intervention), including those undergoing more complex procedures. By studying treatment outcomes over time, the Registry aims to better understand which therapies work best for different groups of patients and to improve future care for people with coronary artery disease.
Read the detailed description
The PCI Registry Basel is established to systematically collect real-world data on all patients (≥18 years) undergoing percutaneous coronary interventions (PCI) at the University Hospital Basel. The primary purpose of the registry is to investigate the best treatment strategies in patients with coronary artery disease (CAD) and their associated outcomes in routine clinical practice, including complex procedures (e.g. chronic total occlusions (CTO), bifurcation lesions, left main interventions), the use of drug-coated balloons (DCB) and bioresorbable scaffolds (BRS), as well as standard drug-eluting stent (DES) implantation.
Data are derived retrospectively from routine clinical practice at the University Hospital Basel. Relevant procedural, clinical, and follow-up information is extracted from existing sources such as the catheterization lab reports, and the electronic health record (Cardioapp). No additional data collection or invasive study-specific interventions are performed for the purpose of this registry.
Where applicable, data from previous research projects or registries may also be incorporated, provided that all legal and ethical requirements are satisfied. All data will be pseudonymised before analysis. A secure decoding key linking registry numbers to patient identifiers is kept separately and is accessible only to authorized personnel under the responsibility of the Principal Investigator.
- Keywords
- Registry, Percutaneous coronary interventions, Coronary artery disease
- Medical subject headings
- Coronary Artery Disease, Coronary Stenosis, Coronary Occlusion
What is being measured
The primary outcome is the main question the study is designed to answer.
Target Vessel Failure (TVF)
Composite endpoint defined as the occurrence of cardiovascular death, target vessel myocardial infarction, or unplanned target vessel revascularisation.
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2026
- Study start1 Oct 2025
- Primary completionOct 2035 (estimated)
- Study completionOct 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Gregor Leibundgut, Prof. Dr. med., Principal investigator, University Hospital, Basel, SwitzerlandJasper Boeddinghaus, PD Dr. med., Principal investigator, University Hospital, Basel, Switzerland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07814157
- Sponsor's protocol ID
- kt26Boeddinghaus2
- Status last verified
- Sep 2026
- First submitted
- 31 Aug 2026
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PCI Registry Basel
- ClinicalTrials.gov ID
- NCT07814157
- Acronym / sponsor ID
- kt26Boeddinghaus2
- Keywords
- Registry, Percutaneous coronary interventions, Coronary artery disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- Oct 2035 (estimated)
- Study completion
- Oct 2035 (estimated)
- First posted
- 10 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This registry aims to learn more about the best ways to treat coronary artery disease. Information from routine medical care will be collected to compare different treatment approaches, including drug-eluting stents, drug-coated balloons (DCB), and bioresorbable scaffolds (BRS), which gradually dissolve over time. The registry will include people with coronary artery disease who receive an intervention (percutaneous coronary intervention), including those undergoing more complex procedures. By studying treatment outcomes over time, the Registry aims to better understand which therapies work best for different groups of patients and to improve future care for people with coronary artery disease.
Detailed description
The PCI Registry Basel is established to systematically collect real-world data on all patients (≥18 years) undergoing percutaneous coronary interventions (PCI) at the University Hospital Basel. The primary purpose of the registry is to investigate the best treatment strategies in patients with coronary artery disease (CAD) and their associated outcomes in routine clinical practice, including complex procedures (e.g. chronic total occlusions (CTO), bifurcation lesions, left main interventions), the use of drug-coated balloons (DCB) and bioresorbable scaffolds (BRS), as well as standard drug-eluting stent (DES) implantation.
Data are derived retrospectively from routine clinical practice at the University Hospital Basel. Relevant procedural, clinical, and follow-up information is extracted from existing sources such as the catheterization lab reports, and the electronic health record (Cardioapp). No additional data collection or invasive study-specific interventions are performed for the purpose of this registry.
Where applicable, data from previous research projects or registries may also be incorporated, provided that all legal and ethical requirements are satisfied. All data will be pseudonymised before analysis. A secure decoding key linking registry numbers to patient identifiers is kept separately and is accessible only to authorized personnel under the responsibility of the Principal Investigator.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consits of patients undergoing percutaneous coronary interventions (PCI) at the University Hospital Basel
Key inclusion criteria (5 listed)
- Patients treated at the University Hospital Basel
- Undergoing complex PCI (e.g. left main, bifurcation, multivessel PCI, rotational atherectomy or other calcium modification, complex anatomy). The definition complex will be a clinical/ procedural/ anatomical definition made by the operator.
- Undergoing CTO or CHIP (Complex High-risk Indicated Patient) procedures
- Treated with a DCB strategy
- Treated with a BRS
Key exclusion criteria (1 listed)
- Patients under 18 years of age
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Target Vessel Failure (TVF)
Time frame: Through study completion, an average of 1 year
Composite endpoint defined as the occurrence of cardiovascular death, target vessel myocardial infarction, or unplanned target vessel revascularisation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
Related trials for Coronary Artery Disease
Recruiting
Multivessel Balloon Occlusion to Investigate Obstructive Coronary Artery Disease and aNgina
Stable Angina, Multivessel Coronary Artery Disease
Not yet recruitingPhase 3
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
Heart Failure Due to Coronary Artery Disease
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruitingObservational study
Prognostic Value of Functional-Nutritional Status in Older Adults With Acute Coronary Syndrome
Acute Coronary Syndromes (ACS)
RecruitingObservational study
Cardiovascular Acoustics for Early Disease Detection
Valvular Heart Disease, Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gregor Leibundgut, Prof. Dr. med. principal investigator
University Hospital, Basel, Switzerland
Jasper Boeddinghaus, PD Dr. med. principal investigator
University Hospital, Basel, Switzerland
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease and Coronary Stenosis, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gregor Leibundgut, Prof. Dr. med. ((0)61 556 58 18 ext. 0041, gregor.leibundgut@usb.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Target Vessel Failure (TVF) (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.